Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 amp TP53 wild-type |
| Therapy | KRT-232 |
| Indication/Tumor Type | osteosarcoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 amp TP53 wild-type | osteosarcoma | sensitive | KRT-232 | Preclinical | Actionable | In a preclinical study, KRT-232 (AMG 232) inhibited tumor growth in osteosarcoma cell line xenograft models with wild-type TP53 and MDM2 amplification (PMID: 25567130, PMID: 24967612). | 24967612 25567130 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24967612) | Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. | Full reference... |
| (25567130) | The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. | Full reference... |